drugset / Trial / NCT01016795
Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma
Phase 2
Terminated
32 enrolled
Aalborg University Hospital
Amgen · collabHelsinki University Central Hospital · collabHerlev Hospital · collabNordic Lymphoma Group · collabOslo University Hospital · collabRigshospitalet, Denmark · collabTurku University Hospital · collabUmeå University · collabUniversity Hospital, Linkoeping · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Clinical Hypothesis: It is expected that by removing chemotherapy and adding ancestim to the mobilization scheme in most of the subjects sufficient PBPC will be harvested with a minimum of toxicity and side effects.
Timeline
- Start
- 1999-01
- Primary completion
- 2000-11
- Completion
- 2009-11
Outcome
Outcome not reported
Stopped: “Study closed Nov 2000 by Amgen, who stopped drug delivery”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | r-metHuSCF | Protein / enzyme biologic | 20 ug/kg | Subcutaneous |
| Comparator | filgrastim | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |